Established care
Your stage and cause drive treatment
Blood-pressure and diabetes control, kidney-protective medicines, and dialysis or transplant planning stay central to your plan when indicated.
Kidney-focused regenerative care
Stem cell therapy for kidney disease in Istanbul, Turkey
A stage-specific program combining nephrology-grade monitoring with cell-based support, transparent Istanbul pricing, and full aftercare.
Conceptual biological visualization
Evidence status
What the evidence can support now
What we add
Support for inflammation and fibrosis
For selected patients, especially with diabetic kidney disease, we add MSC-based protocols studied for safety and effects on inflammatory and fibrotic pathways.
What we won't promise
Guaranteed kidney regeneration
We will not promise restored filtration or dialysis avoidance. We're upfront about what the evidence currently supports so you can decide with confidence.
A direct answer
The short answer
Our program applies cell-based support for selected kidney disease alongside your existing nephrology care, never in place of it. Your protocol is built around your CKD stage, cause, and current treatment, with physician oversight throughout your stay in Istanbul. Results vary between patients and stem cell therapy is not a guaranteed cure.
Start with the phenotype
Your kidney diagnosis shapes the plan
CKD stage alone isn't enough. Cause, trajectory, albuminuria, complications, and remaining kidney reserve all shape your protocol.
Your kidney-protection plan comes first
Regenerative support never interrupts the measures proven to slow progression and protect your heart.
- Confirm cause, CKD stage, eGFR trajectory, and urine albumin-to-creatinine ratio
- Optimize blood pressure, diabetes, and cardiovascular risk
- Use ACE inhibitor or ARB and SGLT2 therapy where guideline-indicated
- Review nephrotoxins, doses, nutrition, anemia, electrolytes, and mineral-bone disease
- Continue dialysis, transplant, or conservative-care planning when appropriate
- 01
Diabetic kidney disease
The setting with the strongest early MSC trial experience and the most established protocol option.
- 02
Glomerular and immune disease
IgA nephropathy, lupus nephritis, and other causes are managed with diagnosis-specific specialist care.
- 03
Inherited disease
ADPKD and monogenic disease call for a different research and treatment conversation.
- 04
Kidney failure
Dialysis, transplantation, and conservative kidney management remain the backbone of care.
Product and route matter
The exact protocol matters
We tell you the disease, source, route, and endpoint behind your specific protocol — not a generic "kidney stem cells" pitch.
- 01
Systemic MSC infusion
Allogeneic or autologous stromal-cell products, studied mainly for safety and biological signals in diabetic kidney disease.
Evidence boundaryWe match the evidence to your specific CKD cause rather than generalizing across all of them.
- 02
Intra-arterial delivery
Some research targets renal circulation more directly for selected candidates.
Evidence boundaryA distinct, more invasive route with its own risk profile that we review with you in detail.
- 03
Renal progenitor and organoid research
Laboratory research explores nephron models, inherited disease, and tissue engineering.
Evidence boundaryLaboratory progress, not yet an available patient treatment.
- 04
Extracellular vesicles
Preclinical work examines acellular signaling products for future protocols.
Evidence boundaryWe track this research closely but don't offer it ahead of clinical validation.
Indexed evidence ledger
The human trials behind our approach
We distinguish measured GFR, estimated GFR, laboratory movement, and true patient-important outcomes — the details most clinic pages skip.
01 NEPHSTROM phase 1b/2a
Open study- Product
- Allogeneic bone-marrow MSC product
- Study design
- Randomized early-phase study in diabetic kidney disease
- Finding
- Supported further safety and signal-finding research.
- Limitation
- First cohort was small; measured GFR matched placebo while exploratory eGFR analyses suggested a signal.
02 Earlier diabetic nephropathy trial
Open study- Product
- Allogeneic mesenchymal precursor cells
- Study design
- Randomized, placebo-controlled clinical study
- Finding
- Examined renal-function signals and safety.
- Limitation
- Early-phase endpoints; efficacy across CKD still needs confirmation.
Measure what changes
How we measure real progress
One creatinine result can shift with hydration or muscle mass. We track trajectory and patient-important events, not a single number.
- 01
Measured and estimated GFR
Related but not interchangeable; serial change matters more than one value.
- 02
Albuminuria
Urine ACR helps describe kidney damage and cardiovascular risk.
- 03
Progression events
Dialysis initiation, transplant, sustained GFR decline, and hospitalization all matter.
- 04
Safety
Infection, immune reactions, volume load, thrombosis, and renal function are actively monitored.
Clinical review before travel
What your free Istanbul evaluation covers
Your review starts with your longitudinal nephrology data so we can confirm eligibility and build a stage-appropriate plan.
Records to send
- Cause of kidney disease, stage, and nephrology summary
- Serial creatinine and eGFR, urine ACR or protein measurements
- Electrolytes, blood count, albumin, diabetes data, and blood pressure
- Kidney biopsy, ultrasound, CT, or MRI when available
- Complete medication list, dialysis schedule, access, and transplant status
Reasons to pause
- Acute kidney injury or rapidly changing renal function
- Active infection, uncontrolled blood pressure, or unstable cardiovascular disease
- A need for urgent dialysis, access management, or transplant assessment
- Any proposal to stop nephrology care or proven kidney-protective medication
Transparent planning
Kidney disease stem cell therapy cost in Turkey
Your written estimate names the exact product, route, hospital component, diagnostic work, observation, and follow-up — and states clearly what's not included, such as ongoing nephrology, dialysis, or transplant care.
For context, our general 2026 MSC planning range is $7,000-$18,000. Your kidney-specific quote is itemized once your protocol and stage are confirmed.
- Renal and cardiometabolic evaluation before travel
- Exact cell product, dose, source, manufacturing, and release testing
- IV versus any invasive vascular route and its hospital requirements
- Observation, laboratory monitoring, and specialist follow-up
Questions patients ask us
- 01
How much does kidney stem cell therapy cost in Istanbul?
- 02
Which CKD cause and stage qualifies for this exact protocol?
- 03
How many days will I need to stay in Istanbul?
- 04
How will treatment stay coordinated with my nephrology, dialysis, or transplant team?
Primary reading
Sources behind this guide
FAQ
Questions about kidney disease
Selected patients, especially with diabetic kidney disease, may benefit from MSC-based support studied for effects on inflammation and fibrosis, always alongside your nephrology plan. Results vary between patients and stem cell therapy is not a guaranteed cure.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.